Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003840 · ClinicalTrials.gov registry record · Phase 1
DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003840: Completed Phase 1 study, sponsored by Wake Forest University Health Sciences.
NCT00003840 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003840, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: DTGM fusion protein may be able to locate cancer cells and stop them from growing. PURPOSE: Phase I/II trial to study the effectiveness of DTGM fusion protein in treating patients who have recurrent or refractory acute myeloid leukemia.
Interventions
- BIOLOGICAL DTGM fusion protein
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2005-07 |
| Phase | Phase 1 |
What the finished NCT00003840 record still lists
NCT00003840 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which DTGM fusion protein is the first listed.
NCT00003840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003840 about?
NCT00003840 is a clinical study titled "DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia". RATIONALE: DTGM fusion protein may be able to locate cancer cells and stop them from growing. PURPOSE: Phase I/II trial to study the effectiveness of DTGM fusion protein in treating patients who have recurrent or refractory acute myeloid leukemia.
What is the current status of trial NCT00003840?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-10. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00003840?
The interventions under investigation include: DTGM fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003840?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia